What question did this study set out to answer?

This trial aims to evaluate the effectiveness of dual anti-CTLA-4 and anti-PD-1 treatment in patients with primary vaginal cancers.

April 12, 2026Open Access

A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: vaginal cancer sub cohort results

Key Points

This trial aims to evaluate the effectiveness of dual anti-CTLA-4 and anti-PD-1 treatment in patients with primary vaginal cancers.
Conducted as a phase II, open-label, multicenter trial
Included patients with various histologies of vaginal cancer
Administered ipilimumab and nivolumab at specified doses
Measured outcomes per RECIST v1.1 for primary and secondary endpoints.
29% objective response rate (ORR) observed
14% of patients achieved complete response lasting 14.8 months
14% of patients attained partial response lasting 45.2 months
43% clinical benefit rate (CBR) reported

Abstract

Objective:The SWOG S1609 Dual Anti-CTLA-4 progression-free survival (PFS), overall survival (OS), clinical benefit rate (CBR; overall response plus stable disease SD 6 months), and toxicity are secondary endpoints.Results: Seven evaluable patients (median age, 60 years; performance status 0-1; no prior exposure to immunotherapy) were analyzed, of whom 3 had adenocarcinoma, 2 had squamous cell carcinoma (SCC), one had small-cell carcinoma and one had undifferentiated histology.The ORR was 29%, with 1 patient (14%) with undifferentiated histology achieving complete response (lasting 14.8 months) and 1 patient with SCC histology (14%) attaining a partial response (lasting 45.2 months).The CBR was 43%.The 6-month PFS rate

Bookmark

View Full Paper

Cite This Study

Chae et al. (Thu,) studied this question.

synapsesocial.com/papers/69db37964fe01fead37c591d https://doi.org/https://doi.org/10.3802/jgo.2026.37.e92

Bookmark

View Full Paper